PharmaEssentia (6446)

Currency in TWD
1,410.00
-90.00(-6.00%)
Closed·
6446 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,405.001,545.00
52 wk Range
397.241,550.00
Key Statistics
Bid/Ask
1,410.00 / 1,415.00
Prev. Close
1,500
Open
1,505
Day's Range
1,405-1,545
52 wk Range
397.24-1,550
Volume
4.99M
Average Volume (3m)
3.59M
1-Year Change
244.3872%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6446 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,216.34
Downside
-13.73%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

PharmaEssentia News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,216.34
(-13.73% Downside)

Earnings

Latest Release
Aug 10, 2026
EPS / Forecast
6.06 / 6.37
Revenue / Forecast
6.86B / 6.88B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 18.50%
Dividend Yield
0.10%
Industry Median 0.23%
Annualised payout
1.49
Paid annually
5-Years Growth
-
Growth Streak

6446 Income Statement

Compare 6446 to Peers and Sector

Metrics to compare
6446
Peers
Sector
Relationship
P/E Ratio
76.6x0.0x−0.4x
PEG Ratio
0.870.000.00
Price/Book
15.9x0.0x2.6x
Price / LTM Sales
28.2x0.0x3.1x
Upside (Analyst Target)
5.7%0.0%47.9%
Fair Value Upside
Unlock0.0%6.3%Unlock

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

Employees
131
Market
Taiwan

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
46.57M11.30%69.86B
Other Institutional Investors
43.71M10.60%65.57B
Public Companies & Retail Investors
321.95M78.10%482.93B
Total
412.24M100.00%618.36B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
National Development Fund, Executive Yuan6.42%26,476,71039,715,065
BlackRock, Inc.3.14%12,958,38119,437,572

People Also Watch

255.00
2317
-1.73%
51.20
3481
+2.20%
2,400.00
2330
+0.21%
39.905
ASX
+0.92%
282.82
CRDO
+8.82%

FAQ

What Is the PharmaEssentia (6446) Stock Price Today?

The PharmaEssentia stock price today is 1,410.00 TWD.

What Stock Exchange Does PharmaEssentia Trade On?

PharmaEssentia is listed and trades on the Taiwan Stock Exchange.

What Is the Stock Symbol for PharmaEssentia?

The stock symbol for PharmaEssentia is "6446."

What Is the PharmaEssentia Market Cap?

As of today, PharmaEssentia market cap is 584.35B TWD.

What Is PharmaEssentia's Earnings Per Share (TTM)?

The PharmaEssentia EPS (TTM) is 18.50.

When Is the Next PharmaEssentia Earnings Date?

PharmaEssentia will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is 6446 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has PharmaEssentia Stock Split?

PharmaEssentia has split 4 times.

How Many Employees Does PharmaEssentia Have?

PharmaEssentia has 131 employees.

What is the current trading status of PharmaEssentia (6446)?

As of Aug 17, 2026, PharmaEssentia (6446) is trading at a price of 1,410.00 TWD, with a previous close of 1,500.00 TWD. The stock has fluctuated within a day range of 1,405.00 TWD to 1,545.00 TWD, while its 52-week range spans from 397.24 TWD to 1,550.00 TWD.

What Is PharmaEssentia (6446) Price Target According to Analysts?

The average 12-month price target for PharmaEssentia is 1,216.34 TWD, with a high estimate of 1700 TWD and a low estimate of 552.26262 TWD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -13.73% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.